Lilly confident of FDA approval for Amyvid, Lechleiter says
Eli Lilly and Co. CEO John Lechleiter said he’s confident of gaining U.S. regulatory approval for a drug to help identify plaque in the brain associated with Alzheimer’s disease.
Eli Lilly and Co. CEO John Lechleiter said he’s confident of gaining U.S. regulatory approval for a drug to help identify plaque in the brain associated with Alzheimer’s disease.
Tony Lennen became president of Community Hospital South in 2009, overseeing a 50-bed expansion that was completed last summer, giving the hospital 150 private rooms. The facility, located along the line between Marion and Johnson counties, competes against nearby facilities run by Franciscan St. Francis Health, Indiana University Health and Johnson Memorial Hospital.
Think galloping health insurance costs are a problem unique to American employers? Think again. Medical costs paid by employer-focused health insurers rose by an average of 10 percent last year—identical to the United States.
The failure of its drug Bydureon to match the performance of Novo’s Victoza trims but doesn’t kill sales prospects for the highly touted diabetes drug.
R. Glenn Hilliard, 68, who has held the chairman's title since September 2003, said he will not seek re-election.
A Terre Haute pharmacist faces a possible 10-year prison sentence if convicted of health care fraud and money laundering in a scheme that netted him more than $3.57 million.
With the company recently doubling in size, CEO Dayton Molendorp wanted another executive to guide the company’s further growth.
Bydureon, the diabetes drug being developed by Amylin Pharmaceuticals Inc., Eli Lilly and Co. and Alkermes Inc., didn’t control the disease better than Novo Nordisk A/S’s Victoza in a study.
The Indianapolis Parks Foundation plans to use a $150,000 grant from Indiana University Health to start an organic farm on the east side of the city benefiting Gleaners Food Bank.
WellPoint Inc. has already more than doubled the enrollment gains it expected in 2011 for national accounts that the health insurer administers for large employers.
The Metropolitan Development Commission awarded the tax abatements for the nursing school, set to open in October, despite opposition from the Nora-Northside Community Council and Metropolitan School District of Washington Township.
Community Health Network won a three-way race for a close partnership with Johnson Memorial Hospital, besting Franciscan St. Francis and Indiana University Health.
Over the next five years, WellPoint Inc. expects the employer-sponsored insurance business to shrink slightly, forcing it to shift its focus to government-sponsored plans.
Advion BioServices is expected to open the lab at Purdue Research Park in Indianapolis in May with 49 employees. Some of the workers may come from Eli Lilly and Co., which is moving its drug-discovery bioanalytical operations to Advion as part of a partnership.
A complaint filed Wednesday by the U.S. government says Lilly’s plant on South Harding Street is emitting high levels of acetonitrile and methanol, considered hazardous air pollutants by the EPA.
David Bredt, vice president of neuroscience research, has resigned “to pursue other opportunities,” according to Lilly spokeswoman Judy Kay Moore. Bredt had overseen Lilly’s development of various drugs, including molecules in late-stage human testing to treat Alzheimer’s and depression.
WellPoint Inc. became the latest health insurer to reward shareholders with a quarterly payout after piling up cash from a string of strong financial performances.
The Carmel-based life and health insurer, in an after-markets announcement, said it earned $168.2 million in the final three months of last year, a big jump from the $18.2 million profit it posted in the same quarter the prior year.
Franciscan Alliance will spend more than $100 million over the next two years to install a common electronic medical record system at its 13 hospitals and more than 165 physician practices. It’s a sign of the growth of the health information technology industry in Indiana, which a new BioCrossroads report says generates $200 million a year in sales and is growing at 8 percent annually.
Indianapolis-based Lilly is developing what it calls “The Mirror Portfolio,” which it expects to grow to 45 to 60 drugs in five years. This month, Lilly announced it had secured venture-capital funding for the first two drugs in this alternative pipeline.